Chimerix(US:CMRX)2023-08-02 16:00Financial Performance - Total revenues for the three months ended June 30, 2023, were $26,000, a decrease from $440,000 in the same period of 2022[28]. - Total revenues for the six months ended June 30, 2023, were $309,000, down from $455,000 in the same period of 2022, reflecting a decrease of 32.2%[28]. - The company reported a gross profit of $26,000 for the three months ended June 30, 2023, compared to $341,000 for the same period in 2022[28]. - The net loss for the three months ended June 30, 2023, was $18,576,000, compared to a net loss of $23,468,000 for the same period in 2022, indicating an improvement of 20.3%[28]. - Net loss for the six months ended June 30, 2023, was $39,948,000, compared to a net loss of $48,235,000 for the same period in 2022, representing a 17.5% improvement[32]. - The company reported a comprehensive loss of $19,158,000 for the three months ended June 30, 2023, compared to a comprehensive loss of $23,463,000 for the same period in 2022, an improvement of 18.5%[28]. Expenses - Research and development expenses for the six months ended June 30, 2023, were $35,748,000, a decrease of 3.6% compared to $37,087,000 for the same period in 2022[28]. - Research and development expenses for the three months ended June 30, 2023, were $16,926,000, compared to $18,047,000 for the same period in 2022, a reduction of 6.2%[28]. - Total operating expenses for the six months ended June 30, 2023, were $45,875,000, down from $48,559,000 in the same period of 2022, reflecting a 5.5% reduction[28]. - General and administrative expenses for the three months ended June 30, 2023, were $4,448,000, down from $5,840,000 in the same period of 2022, a decrease of 23.8%[28]. Cash and Assets - Cash and cash equivalents as of June 30, 2023, were $20,099,000, down from $25,842,000 at the end of 2022, indicating a decrease of 22.5%[26]. - Total assets as of June 30, 2023, were $241,085,000, a decrease from $279,341,000 at the end of 2022, representing a decline of 13.7%[26]. - The company had total stockholders' equity (deficit) of $224,112,000 as of June 30, 2023, compared to $256,857,000 at the end of 2022, indicating a decrease of 12.8%[30]. - The accumulated deficit as of June 30, 2023, was $753,377,000, an increase from $713,429,000 as of December 31, 2022[30]. - Cash flows used in operating activities for the six months ended June 30, 2023, were $36,567,000, compared to $34,007,000 for the same period in 2022, showing an increase of 7.5%[32]. Company Information - Chimerix, Inc. is a Delaware corporation and has obtained a registered trademark for Chimerix® in the United States[38]. - The company is classified as a smaller reporting company and has not elected to use the extended transition period for complying with new financial accounting standards[36]. - The common stock of Chimerix, Inc. is traded on The Nasdaq Global Market under the symbol CMRX[36].